|Videos|September 25, 2016

Do All Babies Congenitally Infected with Zika Develop Microcephaly?

Pedro Fernando da Costa Vasconcelos, MD, PhD, director of WHO Collaborating Center for Arbovirus and Research, Evandro Chagas Institute, discusses the likelihood that fetuses congenitally infected with the Zika virus will develop related complications, such as microcephaly.

Pedro Fernando da Costa Vasconcelos, MD, PhD, director of WHO Collaborating Center for Arbovirus and Research, Evandro Chagas Institute, discusses the likelihood that fetuses congenitally infected with the Zika virus will develop related complications, such as microcephaly.

Interview Transcript (slightly modified for readability)

“[Will] all babies [congenitally infected with Zika virus] develop [complications]? No. You have [a] cohort of pregnant women [from] different places in Brazil that have been followed and we have observed, ourselves and [from] others’ research, that only a small percentage of pregnant women will transmit the virus to [their] fetuses, and the babies will [be] born with microcephaly. Different studies [have] estimated [that] between 1% [and] 13% of these babies will develop severe malformation and microcephaly; not all pregnant women [infected during pregnancies] will [cause] severe [complications] for their babies.

I think that it’s important to remember that almost all infectious disease [have] a large range that range from asymptomatic infections to severe, fatal disease. It’s interesting to observe that, for example, that the percentage of severe disease [resulting from a Zika virus infection], is around 1%, [for] yellow fever [it’s] around 15%. So now, trying to estimate the severity of [Zika virus infection], I’m sure that not all fetuses that [are] infected will present [with] severe disease. It’s important to [keep] this in mind, because the number of infected babies that will not present [with complications] perhaps can be higher than the number of babies that will present [with] severe disease, like microcephaly or other malformations. This is natural because all infectious diseases have a range of the disease’s severity. In [the] case of Zika, it is estimated that around 80% of all infections will be asymptomatic, [meaning infection] will not cause symptoms.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.